Biotech Startups

Causeway Sensors develops nanotechnology-based sensors for applications in biotech and therapeutics production. The company commercializes advanced nanosensing technology for use in bioproduction settings to improve patient outcomes.

1 investor

Cbio develops next-generation T-cell therapies for solid tumors, which account for the majority of cancers. Its lead product, novoleucel, is a minimally invasive cell therapy designed to improve clinical outcomes and survival for late-stage cancer patients.

1 investor

CBSET is a preclinical research organization providing in vivo evaluation and development services for novel medical devices, drugs, and cell-based therapeutics, along with histopathology, morphometry, and physician training. It serves medical device and biotech companies from its facility in Waltham, Massachusetts.

1 investor

CC Bio develops synthetic biology-based therapeutics to treat microbiome-related diseases by engineering and editing the microbiome with precision. The company uses its proprietary Zeus platform to discover and optimize first-in-class treatments for patients seeking alternatives to antibiotics.

1 investor

This site publishes articles about regulatory affairs for immunotherapy, covering topics such as EMA approval processes, orphan drug designation, biomarkers, clinical trials, and compliance in manufacturing. It appears to be a content/blog resource rather than a product company.

1 investor

Cebina is an early-stage biotech investor and incubator that funds and de-risks pre-company and startup drug development projects across pre-seed, seed, and Series A stages. It focuses on therapeutic areas including cardiovascular and metabolic diseases, lung fibrosis, cancer immunotherapy, and anti-infectives, and also pursues co-development and licensing partnerships.</parameter> <parameter name="founders">[]

1 investor

Cedar Health Research operates clinical research services for community-based healthcare providers, connecting patient populations with clinical trials through partnerships and EMR abstraction technology. The company aims to ensure clinical trial participants reflect the broader patient population bearing disease burden.

1 investor

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

1 investor

Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.

1 investor

1 investor

Cell Invent develops human disease models using reprogrammed Alzheimer patient cells to identify new therapeutic approaches for Alzheimer's disease. The company applies proprietary cellular research technology from Lund University to drug discovery and disease modeling for the neurodegenerative disease market.

1 investor

Cell-Easy is a contract development and manufacturing organization (CDMO) specialized in process development and GMP manufacturing of cell therapies and Advanced Therapy Medicinal Products (ATMPs), including T-cells, NK cells, MSCs, and iPSCs. It serves academic laboratories, biotech, and pharma companies from early development through clinical-stage manufacturing.

1 investor

Cell4Food develops cellular agriculture technology to produce seafood—including fish, mollusks, and crustaceans—from cell cultures using bioreactors. The company targets sustainable food production with lower environmental impact than traditional aquaculture.

1 investor

CellaraRx develops Horizen, a platform that uses single-cell RNA sequencing, digital pathology, and AI to help clinicians and drug developers predict patient response to cancer treatments before clinical trial enrollment. The platform identifies tumor resistance mechanisms and tissue drug accessibility to improve patient stratification and trial success rates.

1 investor

Cellarim produces beauty and skincare ingredients using enzymatic, cell-free synthesis rather than extraction, fermentation, or conventional chemical methods. It positions its enzyme-based approach as a way to make purer, more scalable, and more sustainable cosmetic ingredients.

1 investor

CellaVision is a provider of digital hematology microscopy solutions including analyzers, instruments, reagents, and software that automate workflow in hematology laboratories. The company serves clinical and veterinary laboratories globally with digital cell morphology tools to minimize human error and streamline data management.

1 investor

Cell BioEngines is a clinical-stage biotech company developing allogeneic "off-the-shelf" cell therapies from "super donor" stem cells, using transgene-free scalable manufacturing and HLA-guided design. It pursues stem cell-derived therapeutics across oncology and regenerative medicine.

1 investor

Cellbox Solutions develops portable incubators with active CO₂ and temperature control to transport living cells and biological samples at constant laboratory conditions (37°C, 5% CO₂). The company serves the global biomedical industry and works with over 150 customers on cell transport logistics.

1 investor

CellBri provides modular, automated cell processing systems for preparing cells for therapeutic applications. The company offers enclosed, turnkey solutions that can automate individual steps or complete workflows, from cell harvesting and separation through expansion and cryopreservation.

1 investor

CellCarta is a contract research organization providing biomarker discovery, assay development, and clinical trial execution services for pharmaceutical companies and biotechs. It offers multi-omic biomarker insights, regulatory-ready data generation, and regulatory support for assay development and IVDR submissions across preclinical and clinical therapeutic programs.

1 investor

The Cell engineers breakthrough medicines using molecular simulation and artificial intelligence to accelerate drug discovery and development.

1 investor

Cellcraft develops cultivated meat technology and bio-manufacturing systems that use AI and bioreactors to produce meat locally without animals. The company enables food producers to manufacture cultured meat tailored to local tastes while reducing environmental impact, antimicrobial resistance, and production costs.

1 investor

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.

1 investor

CELLECT develops nanomaterial-embedded menstrual products (tampons and pads) that non-invasively collect and preserve DNA from menstrual blood for screening of HPV, cervical cancer, and STDs. The collection system is compatible with existing diagnostic assays and targets women seeking an at-home alternative to Pap smears, including underserved communities.

1 investor